Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer.

ABSTRACT:

Objective

To compare effects and adverse events of anti-programmed cell death protein 1 (anti-PD-1) antibody combined with chemoradiotherapy (CRT) and CRT alone as the initial treatment in locally advanced esophageal squamous cell carcinoma (ESCC).

Methods

We retrospectively reviewed locally advanced ESCC patients who received Anti-PD-1+CRT as initial treatment at 3 institutions. Primary outcomes of interest were progression-free survival (PFS) and overall survival (OS); secondary outcomes were objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and treatment-related adverse events (AEs) including immune-related adverse events (irAEs).

Results

At data cutoff, 81 patients were included (30 Anti-PD-1+CRT, 51 CRT). Median follow-up was

SUBMITTER: Ma J 

PROVIDER: S-EPMC9947779 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature